Filtered By:
Source: American Heart Journal
Education: Study
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 295 results found since Jan 2013.
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial
Conclusions . Despite its higher acquisition cost, edoxaban is an economically attractive alternative to warfarin for the prevention of stroke and SE in patients with atrial fibrillation and creatinine clearance≤95mL/min. These results were robust to variation of key model parameters, including assumptions regarding the cost and quality-of-life impact of stroke and bleeding events, and were favorable across both CHADS2 score stroke-risk categories.
Source: American Heart Journal - September 26, 2015 Category: Cardiology Source Type: research
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research
Assessment of the Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at High-Risk for Vascular Outcomes – Rationale and Design of the ACCELERATE Trial
Conclusions ACCELERATE will establish whether the CETP inhibition by evacetrapib improves cardiovascular outcomes in patients with high risk vascular disease.
Source: American Heart Journal - September 16, 2015 Category: Cardiology Source Type: research
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation
Conclusions Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV mortality in patients with AF despite anticoagulant treatment.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction
Conclusions Reverse LV remodeling can occur after high-risk PCI in patients with complex coronary artery disease and reduced EF and is associated with improved clinical outcomes.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis
Conclusion In patients with MHV on anticoagulation, eGFR is an independent predictor of major bleeding and death and not TE.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
Reducing Cardiovascular Risk through Treatment of Obstructive Sleep Apnea: Two Methodological Approaches
Publication date: Available online 11 September 2015 Source:American Heart Journal Author(s): Klar Yaggi, Murray A. Mittleman, Dawn M. Bravata, John Concato, James Ware, Catherine M. Stoney, Susan Redline Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by observational investigations showing an independently increased risk of ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep apnea, reverses airway obstruction ...
Source: American Heart Journal - September 11, 2015 Category: Cardiology Source Type: research
The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial)
This article reports the rationale for the Brazilian Cardioprotective Nutritional Program (BALANCE Program) Trial. This pragmatic, multicenter, nationwide, randomized, concealed, controlled trial was designed to investigate the effects of the BALANCE Program in reducing cardiovascular events. The BALANCE Program consists of a prescribed diet guided by nutritional content recommendations from Brazilian national guidelines using a unique nutritional education strategy, which includes suggestions of affordable foods. In addition, the Program focuses on intensive follow-up through one-on-one visits, group sessions, and phone c...
Source: American Heart Journal - August 16, 2015 Category: Cardiology Source Type: research
sRAGE and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study
Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.
Source: American Heart Journal - August 14, 2015 Category: Cardiology Source Type: research
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial
Conclusion Although considerably less frequent than stroke, systemic embolism is associated with significant morbidity and mortality in patients with AF. Although the overall number of events was too small to show a significant difference in the risk of SEE between edoxaban and warfarin, a meta-analysis of all the NOAC trials demonstrates that NOACs significantly reduce the risk of SEE compared with warfarin.
Source: American Heart Journal - August 6, 2015 Category: Cardiology Source Type: research
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients aged 70years and older – Rationale and design of the POPular AGE-study
Conclusion The POPular AGE is the first randomized controlled trial that will assess whether the treatment strategy with clopidogrel will result in fewer bleeding events without compromising the net clinical benefit in patients≥70years of age with NSTE-ACS, when compared with a treatment strategy with ticagrelor or prasugrel.
Source: American Heart Journal - August 5, 2015 Category: Cardiology Source Type: research
Real-Time Physiologic Biomarker for Prediction of Atrial Fibrillation Recurrence, Stroke, and Mortality After Electrical Cardioversion − A Prospective observational study
Conclusions Patients with decreased LAAEV have an increased risk of AF recurrence, stroke and mortality following successful ECV. Real-time measurement of LAAEV by TEE may be a useful physiologic biomarker for individualizing treatment decisions in patients with AF.
Source: American Heart Journal - July 31, 2015 Category: Cardiology Source Type: research
Rationale and Design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients with Multivessel Coronary Artery Disease
Conclusion The FAME 3 study will compare in a multicenter, randomized fashion FFR-guided PCI with contemporary drug-eluting stents to CABG in patients with three-vessel coronary artery disease.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: from the ACCOAST study
Conclusions In ACCOAST, early (<2.98 days) surgical revascularization carried increased risk of bleeding and ischemic complications without affecting all-cause mortality through 30 days. Baseline troponin and prasugrel pretreatment did not impact ischemic clinical outcomes.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
Genetic Mutations in African Patients with Atrial Fibrillation: Rationale and Design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)
Conclusion This is the first study determining genetic associations in valvular and non-valvular atrial fibrillation in sub-Saharan Africa with a control population. The results advance knowledge about atrial fibrillation and will enhance international efforts to decrease atrial fibrillation-related morbidity.
Source: American Heart Journal - June 16, 2015 Category: Cardiology Source Type: research
